Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1Dermatologic 1

Conditions

Carcinoma, Non-Small-Cell Lung 63Neoplasms 36Colorectal Neoplasms 34Neoplasm Metastasis 32Ovarian Neoplasms 26Breast Neoplasms 26Recurrence 25Prostatic Neoplasms 25Pancreatic Neoplasms 25Melanoma 24Squamous Cell Carcinoma of Head and Neck 21Multiple Myeloma 21Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lung Neoplasms 18Glioblastoma 18Endometrial Neoplasms 16Triple Negative Breast Neoplasms 15Lymphoma, Non-Hodgkin 15Lymphoma, Large B-Cell, Diffuse 15Burkitt Lymphoma 14Stomach Neoplasms 13Leukemia, Myeloid, Acute 13Colonic Neoplasms 13Small Cell Lung Carcinoma 12Glioma 12Carcinoma, Renal Cell 12Sarcoma 11Gastrointestinal Neoplasms 11Lymphoma, Follicular 10Lymphoma 10

Interventions

Paroxetine 1Itraconazole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Lethal Congenital Contracture Syndrome 2 × 30 days × Clear all
NCT07070232 2026-05-22

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

BioNTech SE

Phase 1/2 Recruiting
980 enrolled
DermatologicGastrointestinalThoracic

Lethal Congenital Contracture Syndrome 2, Carcinoma, Non-Small-Cell Lung, Melanoma, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡